Page 3 - Nathan Kaiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Small Business Administration announced hard-hit local restaurants and bars can apply for a share of $26 billion in COVID-19 relief beginning next Monday.

Posted on 17160 Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta ® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The approval makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy approved for patients with indolent follicular lymphoma, follows FDA Breakthrough Therapy Designation and a priority review,...

ECN Crowdcon 2020: Opportunities and Challenges for the European Crowdfunding Industry in the New Decade February 21, 2021 @ 9:02 pm By André Jasch The European crowdfunding industry is merging into a harmonized market – with major implications for how companies raise capital and investors access investment opportunities. The opportunities and challenges arising from this were also at the center of the ECN Crowdfunding Convention 2020 (ECN CrowdCon). This article gives you a detailed report of the 9th ECN CrowdCon. ECN CrowdCon is organized annually by the European Crowdfunding Network (EC...

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the BenefitRisk Profile Based on Data from a Cohort of ZUMA-1 Patients — — Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts — Kite, a Gilead Company today announced findings from a new analysis of the ZUMA-1 trial of Yescarta ® in adult patients with relapsed or refractory large B-cell lymphoma . Results … — Use of...

Kite Appoints Frank Neumann as Worldwide Head of Clinical Development Industry Leader in Cell Therapy and Oncology Drug Development Positioned for Continued Advancement of Kite’s Clinical Programs — Kite, a Gilead Company today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will lead Kite’s Clinical Development organization across hematological malignancies and solid tumors. Ken … — Industry Leader in Cell Therapy and Oncology Drug Development Positioned for Continued Advancement of Kite’...